Intercell AG was a biotechnology company based in Vienna which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology in Vienna.It employs 400 people in Austria, Scotland and the United States.It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.The most important projects of Intercell are: Vaccine against Japanese encephalitis Therapeutic vaccine against hepatitis C Antigen identification program and adjuvant technologies. Vaccine Enhancement Patch to improve prevention against pandemic influenza ↑ 1.0 1.1 1.2 1.3 1.4 1.5 ↑ ↑ ↑ ↑ ↑ ↑ ↑ Wikipedia.
Intercell | Date: 2013-01-09
Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of
Intercell | Date: 2013-03-12
The present invention relates to a new use of a vaccine comprising a fusion protein that comprises the
Intercell | Date: 2013-03-06
Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2 deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2 deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5 or 3 ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs.
Intercell | Date: 2013-03-14
The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a
Intercell | Date: 2013-05-06
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from